Tgf-β1 produced by activated CD4 + T Cells Antagonizes T Cell Surveillance of Tumor Development

Donkor, Moses K.; Sarkar, Abira; Li, Ming O.

doi:10.4161/onci.1.2.18481

Cited by 48TGF-β signaling in diseasesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Tgf-β1 produced by activated CD4 + T Cells Antagonizes T Cell Surveillance of Tumor Development

Open access

Donkor, Moses K., Sarkar, Abira, Li, Ming O.·2012·OncoImmunology

DOI 10.4161/onci.1.2.18481PMC PMC3376999

Open this paper in CoChat — free account

Abstract

TGFβ1 is a regulatory cytokine with a crucial function in the control of T cell tolerance to tumors. Our recent study revealed that T cell-produced TGFβ1 is essential for inhibiting cytotoxic T cell responses to tumors. However, the exact TGFβ1-producing T cell subset required for tumor immune evasion remains unknown. Here we showed that deletion of TGFβ1 from CD8(+) T cells or Foxp3(+) regulatory T (Treg) cells did not protect mice against transplanted tumors. However, absence of TGFβ1 produced by activated CD4(+) T cells and Treg cells inhibited tumor growth, and protected mice from spontaneous prostate cancer. These findings suggest that TGFβ1 produced by activated CD4(+) T cells is a necessary requirement for tumor evasion from immunosurveillance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.4161/onci.1.2.18481

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Treg cells contribute to macrophage and neutrophil polarization towards a regenerative rather than inflammatory cell state.
“and contribute to macrophage and neutrophil polarization towards a regenerative rather than inflammatory cell state58,63,82,145,172,173,218,219.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [63]
Treg cells functionally repress the tumor-killing activity of CD8+ T cells through various activities, including TGF-β1 activation.
“These then functionally repress, through various activities, including TGF-β1 activation82,145, the tumor-killing activity of CD8+ T cells 58,63,82,145,218,219”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [63]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · see citing works
TGFβ in Cancer
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · see citing works
Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985 · see citing works
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · see citing works
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,095 · see citing works
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967 · see citing works
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in tumor research · doi:10.1159/000386035 · Cited by 1,659 · see citing works
Making sense of latent TGFβ activation
Annes, J. P., Munger, J. S., & Rifkin, D. B. (2002) · Journal of Cell Science · doi:10.1242/jcs.00229 · Cited by 1,624 · see citing works
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438 · see citing works
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355 · see citing works
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · see citing works
Prostate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F. J., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,296 · see citing works
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L. H., Brockstedt, D. G., Weber, J. S., Johnson, D. L., Swetter, S. M., Thompson, J. A., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,117 · see citing works
TGF-β: A Master of All T Cell Trades
Li, M. O., & Flavell, R. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.025 · Cited by 888 · see citing works
Self-citation
Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms
Li, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 794 · see citing works
Self-citation
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770 · see citing works
T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation
Li, M. O., Wan, Y. Y., & Flavell, R. A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.014 · Cited by 728 · see citing works
Self-citation
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., den Eynde, B. J. V., & van der Bruggen, P. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651 · see citing works
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D. P., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 577 · see citing works
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 537 · see citing works
Loss of integrin αvβ8 on dendritic cells causes autoimmunity and colitis in mice
Travis, M. A., Reizis, B., Melton, A. C., Masteller, E., Tang, Q., Proctor, J. M., Wang, Y., Bernstein, X., Huang, X., Reichardt, L. F., et al. (2007) · Nature · doi:10.1038/nature06110 · Cited by 503 · see citing works
Cellular Mechanisms of Fatal Early-Onset Autoimmunity in Mice with the T Cell-Specific Targeting of Transforming Growth Factor-β Receptor
Marie, J. C., Liggitt, D., & Rudensky, A. Y. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.012 · Cited by 480 · see citing works
Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β
Liu, V. C., Wong, L. Y., Jang, T. L., Shah, A. H., Park, I. I., Yang, X. J., Zhang, Q., Lonning, S. M., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453 · see citing works
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. J. F. (2005) · Nature · doi:10.1038/nature03954 · Cited by 439 · see citing works
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.
Torre‐Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H. W., Moses, H. L., & Rowley, D. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1486 · Cited by 403 · see citing works
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ
Street, S. E. A., Trapani, J. A., MacGregor, D. P., & Smyth, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020063 · Cited by 375 · see citing works
RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305 · see citing works
Regulatory T cells in immune surveillance and treatment of cancer
Yamaguchi, T., & Sakaguchi, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.005 · Cited by 263 · see citing works
Autocrine Transforming Growth Factor-β1 Promotes In Vivo Th17 Cell Differentiation
Gutcher, I., Donkor, M. K., Ma, Q., Rudensky, A. Y., Flavell, R. A., & Li, M. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.005 · Cited by 243 · see citing works
Self-citation
An Anti–Transforming Growth Factor β Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments
Nam, J., Terabe, M., Mamura, M., Kang, M., Chae, H., Stuelten, C. H., Kohn, E. A., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 233 · see citing works
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.
Letterio, J. J., Geiser, A. G., Kulkarni, A. B., Dang, H., Kong, L., Nakabayashi, T., Mackall, C. L., GRESS, R. E., & Roberts, A. B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119017 · Cited by 232 · see citing works
Ulcerative colitis and autoimmunity induced by loss of myeloid αv integrins
Lacy‐Hulbert, A., Smith, A. M., Tissire, H., Barry, M., Crowley, D. G., Bronson, R. T., Roes, J., Savill, J., & Hynes, R. O. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707421104 · Cited by 225 · see citing works
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution.
Klein, G., & Klein, E. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.5.2121 · Cited by 168 · see citing works
Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-β–Insensitive CD8+ T Cells: Eradication of Autologous Mouse Prostate Cancer
Zhang, Q., Yang, X. J., Pins, M., Javonovic, B., Kuzel, T. M., Kim, S., Parijs, L. V., Greenberg, N. M., Liu, V., Guo, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3169 · Cited by 146 · see citing works
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
Donkor, M. K., Sarkar, A., Savage, P. A., Franklin, R. A., Johnson, L. K., Jungbluth, A. A., Allison, J. P., & Li, M. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.019 · Cited by 130 · see citing works
Self-citation
Tumor-Derived TGF-β Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine
Kao, J. Y., Gong, Y., Chen, C.-M., Zheng, Q.-D., & Chen, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3806 · Cited by 118 · see citing works
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
Willimsky, G., Czéh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., & Blankenstein, T. J. F. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072016 · Cited by 111 · see citing works
Specificity in cancer immunotherapy
Schietinger, A., Philip, M., & Schreiber, H. W. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.07.001 · Cited by 109 · see citing works
Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients
Buck, M. B., Fritz, P., Dippon, J., Zugmaier, G., & Knabbe, C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0320-03 · Cited by 100 · see citing works
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
Savage, P. A., Vosseller, K., Kang, C., Larimore, K., Riedel, E., Wojnoonski, K., Jungbluth, A. A., & Allison, J. P. (2008) · Science · doi:10.1126/science.1148886 · Cited by 92 · see citing works
Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse.
Kobayashi, S., Yoshida, K., Ward, J. M., Letterio, J. J., Longenecker, G., Yaswen, L. R., Mittleman, B. B., Mozes, E., Roberts, A. B., Karlsson, S., et al. (1999) · PubMed · Cited by 65 · see citing works
Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor ?? Antibody and Interleukin-2
Wojtowicz‐Praga, S., Verma, U. M., Wakefield, L. M., López-Jamar, J. M. E., Hartmann, D., & Mazumder, A. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199605000-00001 · Cited by 60 · see citing works
Dysfunctional Transforming Growth Factor-β Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model
Pu, H., Collazo, J., Jones, E., Gayheart, D. T., Sakamoto, S., Vogt, A. P., Mitchell, B. L., & Kyprianou, N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0758 · Cited by 60 · see citing works
β2-Microglobulin-Deficient Background Ameliorates Lethal Phenotype of the TGF-β1 Null Mouse
Kobayashi, S., Yoshida, K., Ward, J. M., Letterio, J. J., Longenecker, G., Yaswen, L. R., Mittleman, B. B., Mozes, E., Roberts, A. B., Karlsson, S., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.4013 · Cited by 58 · see citing works
The adaptive immune response to sporadic cancer
Willimsky, G., & Blankenstein, T. J. F. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00578.x · Cited by 55 · see citing works

Flagged first, then by citations

Sorted by citations

TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,270 · see citing works
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
TGF-β: Guardian of T Cell Function
Oh, S. A., & Li, M. O. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301843 · Cited by 320 · see citing works
Self-citation
Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells
Li, S., Liu, M., Do, M. H., Chou, C., Stamatiades, E. G., Nixon, B. G., Shi, W., Zhang, X., Li, P., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2850-3 · Cited by 242 · see citing works
Self-citation
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 216 · see citing works
TGF-beta: a master immune regulator
Larson, C., Oronsky, B. T., Carter, C. A., Oronsky, A. L., Knox, S. J., Sher, D. J., & Reid, T. R. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1744568 · Cited by 211 · see citing works
TGF-β suppresses type 2 immunity to cancer
Liu, M., Kuo, F., Capistrano, K. J., Kang, D., Nixon, B. G., Shi, W., Chou, C., Do, M. H., Stamatiades, E. G., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2836-1 · Cited by 189 · see citing works
Self-citation
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177 · see citing works
Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
Zhang, Q., Yin, W., Xia, Y., Yi, Y.-Y., He, Q., Wang, X., Ren, H., & Zhang, D. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.28 · Cited by 162 · see citing works
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective
Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 138 · see citing works
Self-citation
Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer
Hofman, P. M., Cherfils‐Vicini, J., Bazin, M., Ilié, M., Juhel, T., Hébuterne, X., Gilson, É., Schmid‐Alliana, A., Boyer, O., Adriouch, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1778 · Cited by 110 · see citing works
Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer
Zou, J. Y., Su, C., Luo, H. H., Lei, Y. Y., Zeng, B., Zhu, H. S., & Chen, Z. G. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26302 · Cited by 90 · see citing works
The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment
Aguilar‐Cázares, D., Chavez-Dominguez, R., Marroquin-Muciño, M., Perez-Medina, M., Benito-Lopez, J. J., Camarena, Á., Rumbo‐Nava, U., & López-González, J. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.929572 · Cited by 85 · see citing works
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
González-Navajas, J. M., Fan, D. D., Yang, S., Yang, F. M., Lozano‐Ruiz, B., Shen, L., & Lee, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625783 · Cited by 75 · see citing works
Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?
Mirzaei, S., Paskeh, M. D. A., Saghari, Y., Zarrabi, A., Hamblin, M. R., Entezari, M., Hashemi, M., Aref, A. R., Hushmandi, K., Kumar, A. P., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.02.094 · Cited by 74 · see citing works
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer
da Silva, H. B., Amaral, E. P., Nolasco, E. L., de Victo, N. C., Atique, R., Jank, C. C., Anschau, V., Zerbini, L. F., & Correa, R. G. (2013) · Prostate Cancer · doi:10.1155/2013/920612 · Cited by 69 · see citing works
Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma–Induced Immune Suppression
Sun, X., Sui, Q., Zhang, C., Tian, Z., & Zhang, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1087 · Cited by 67 · see citing works
Immunity beyond cancer cells: perspective from tumor tissue
Gao, S., Hsu, T.-W., & Li, M. O. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.007 · Cited by 59 · see citing works
Self-citation
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1636034 · Cited by 51 · see citing works
Tumor-Derived Transforming Growth Factor-β is Critical for Tumor Progression and Evasion from Immune Surveillance
Li, Z., Zhang, L., Zhang, H.-R., Tian, G., Tian, J., Mao, X., Jia, Z., Meng, Z., Zhao, L., Yin, Z., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.13.5181 · Cited by 48 · see citing works
TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
Li, G., Srinivasan, S., Wang, L., Ma, C., Guo, K., Xiao, W., Liao, W., Mishra, S., Zhang, X., Qiu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33768-x · Cited by 39 · see citing works
Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models
Webster, B., Xiong, Y., Hu, P., Wu, D., Alabanza, L. M., Orentas, R. J., Dropulić, B., & Schneider, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.006 · Cited by 35 · see citing works
MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine
Guo, M., Luo, B., Pan, M., Li, M., Zhao, F., & Dou, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106631 · Cited by 33 · see citing works
Self-citation
A tumor-specific mechanism of T reg enrichment mediated by the integrin αvβ8
Seed, R., Kobayashi, K., Ito, S., Takasaka, N., Cormier, A., Jespersen, J. M., Publicover, J., Trilok, S., Combes, A. J., Chew, N. W., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf0558 · Cited by 30 · see citing works
TGFβ: Signaling Blockade for Cancer Immunotherapy
Chen, S., Mamaï, O., & Akhurst, R. J. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-103554 · Cited by 28 · see citing works
Modes of Communication between T Cells and Relevance for Immune Responses
Uhl, L. F. K., & Gérard, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082674 · Cited by 24 · see citing works
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Kejík, Z., Kaplánek, R., Dytrych, P., Masařík, M., Veselá, K., Abramenko, N., Hoskovec, D., Vašáková, M., Králová, J., Pavel Martasek, E., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111879 · Cited by 23 · see citing works
T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development
Vähätupa, M., Aittomäki, S., Córdova, Z. M., May, U., Prince, S., Uusitalo‐Järvinen, H., Järvinen, T. A. H., & Pesu, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1245266 · Cited by 21 · see citing works
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer
Zhang, Q., Jiang, L., Wang, W., Huber, A. K., Valvo, V. M., Jungles, K. M., Holcomb, E. A., Pearson, A. N., The, S., Wang, Z., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.168824 · Cited by 20 · see citing works
Metabolic rewiring directs melanoma immunology
Sun, N., Tian, Y., Chen, Y., Guo, W., & Li, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909580 · Cited by 17 · see citing works
T cell- but not tumor cell-produced TGF-β1 promotes the development of spontaneous mammary cancer
Sarkar, A., Donkor, M. K., & Li, M. O. (2011) · Oncotarget · doi:10.18632/oncotarget.403 · Cited by 14 · see citing works
Self-citation
Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor
Yao, Y., Li, J., Qu, K., Wang, Y., Wang, Z., Lu, W., Yu, Y., & Wang, L. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03315-0 · Cited by 12 · see citing works
Rapamycin Combined with Immature Dendritic Cells Attenuates Obliterative Bronchiolitis in Trachea Allograft Rats by Regulating the Balance of Regulatory and Effector T Cells
Dong, M., Wang, X., Liu, J., Zhao, Y., Chen, X., Li, K.-Q., & Li, G. (2015) · International Archives of Allergy and Immunology · doi:10.1159/000437207 · Cited by 10 · see citing works
The differentiation state of the Schwann cell progenitor drives phenotypic variation between two contagious cancers
Owen, R. S., Ramarathinam, S. H., Bailey, A. G., Gastaldello, A., Hussey, K., Skipp, P. J. S., Purcell, A. W., & Siddle, H. V. T. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010033 · Cited by 9 · see citing works
Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer
Yang, F., Li, J., Ge, Q., Zhang, Y., Zhang, M., Zhou, J., Wang, H., Du, J., Gao, S., Liang, C. Y., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115669 · Cited by 9 · see citing works
Progress in the relationship between P2X7R and colorectal cancer
Bai, X., Li, X., Qiao, C., Tang, Y., Zhao, R., & Peng, X. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07939-4 · Cited by 9 · see citing works
RETRACTED ARTICLE: Molecular and therapeutic effect of CRISPR in treating cancer
Rodrigo, S., Senasinghe, K., & Quazi, S. (2023) · Medical Oncology · doi:10.1007/s12032-022-01930-6 · Cited by 9 · see citing works
Retracted
Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy
de Folmont, A. D. T., Bourhis, J.-H., Chouaı̈b, S., & Terry, S. (2021) · Immuno · doi:10.3390/immuno1030010 · Cited by 8 · see citing works
Frequency of Effector Memory Cells Expressing Integrin α4β7 Is Associated With TGF-β1 Levels in Therapy Naïve HIV Infected Women With Low CD4+ T Cell Count
Kasarpalkar, N., Bhowmick, S., Patel, V. V., Savardekar, L., Agrawal, S. R., Shastri, J. S., & Bhor, V. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651122 · Cited by 6 · see citing works
Ex vivo interaction between blood components and hormone-dependent breast cancer cells induces alterations associated with epithelial-mesenchymal transition and thrombosis
Augustine, T. N., Pather, K., Mak, D., Klonaros, D., Xulu, K. R., Dix‐Peek, T., Duarte, R. A. B., & van der Spuy, W. J. (2020) · Ultrastructural Pathology · doi:10.1080/01913123.2020.1749197 · Cited by 3 · see citing works
TGF-β3 promotes vascular normalization of prostate cancer to potentiate immunotherapy and chemotherapy
Teng, Q., Wang, N., Lei, H., Tong, T., Guan, Y., Huang, M., Cao, F., Xu, B., Yang, J., Huo, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04103-2 · Cited by 2 · see citing works
Exploring the toxicological mechanisms of atrazine in prostate cancer by network toxicology and molecular docking
Mi, J., Wang, S., Hong, Y., Wu, S., & Wei, G. (2025) · Reproductive Toxicology · doi:10.1016/j.reprotox.2025.109001 · Cited by 2 · see citing works
Strategies to Target Tumor Immunosuppression
Draghiciu, O., Nijman, H. W., & Daemen, T. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_5 · Cited by 1 · see citing works
Transforming Growth Factor-β1 and Tumor Development
Dahl, L. (2023) · Science Insights · doi:10.15354/si.23.re298 · Cited by 1 · see citing works
IMMUNOTHERAPY IN ADVANCED HEPATOCELLULAR CANCER
Volovăț, S. R., & Volovăț, C. C. (2018) · The Medical-Surgical Journal
Biosimilars in Prostate Cancer
Patel, P., Patel, Y. P., Patel, S. G., Patel, A. S., Ganpule, A. P., & Pandey, S. N. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_6
Identification of immune escape-related prognostic genes and immune infiltration analysis in hepatocellular carcinoma based on bioinformatics
Wu, X., Wei, D., Zhu, Y., Zhao, S.-L., Liu, L., Tian, F.-M., Liu, X., & Shi, Z. X. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102181
TGF-β Signaling in Cancer Immunity: Immune Suppression, Stromal Remodeling, and Therapeutic Targeting
Jiang, M., Zhang, K., Zheng, X., Bo, Z., & Wei, R. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.17

Do not distribute. Tgf-b1 produced by activated CD4+ T Cells Antagonizes T Cell Surveillance of Tumor Development
Donkor, M. K., Sarkar, A., & Li, M. O. (2016)
Self-citation
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
Donkor, M. K., Sarkar, A., Savage, P. A., Franklin, R. A., Johnson, L. K., Jungbluth, A. A., Allison, J. P., & Li, M. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.019 · Cited by 130 · see citing works
Self-citation
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-beta 1 Cytokine
Donkor, M. K., Sarkar, A., Savage, P. A., Franklin, R. A., Johnson, L. K., Jungbluth, A. A., Allison, J. P., & Li, M. O. (2011) · ResearchOnline at James Cook University (James Cook University) · Cited by 3 · see citing works
Self-citation
T cell- but not tumor cell-produced TGF-β1 promotes the development of spontaneous mammary cancer
Sarkar, A., Donkor, M. K., & Li, M. O. (2011) · Oncotarget · doi:10.18632/oncotarget.403 · Cited by 14 · see citing works
Self-citation
TGF-β Dependent T-Cell Regulation in Colitis and Colon Cancer
Becker, C., & Neurath, M. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-293-9_11

Authors: Donkor, M. K., Sarkar, A., & Li, M. O.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Li, Ming O.
ORCID: Li, Ming O.
Venue: OncoImmunology
Publisher: Informa UK Limited
Published: 2012-03
Volume: 1
Issue: 2
Pages: 162-171
ISSN: 2162-4011 (ISSN-L)
2162-402X
DOI: 10.4161/onci.1.2.18481
PMC: PMC3376999
OpenAlex: W2079302065
Cited by: 48
References: 46
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 7 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 3
FWCI: 0.90
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
Locations: OncoImmunology (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: TGF-β1, CD4+ T cells, regulatory T cells, tumor immune evasion, tumor surveillance, CD8+ T cell cytotoxicity, prostate cancer, tumor growth, T cell tolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tgf-β1 produced by activated CD4 + T Cells Antagonizes T Cell Surveillance of Tumor Development

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks